Testing DDY391 for Sjögren's disease
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Sjögren's disease, confirmed by a blood test for anti-Ro antibodies or a biopsy of your salivary gland.
- You cannot have another active autoimmune disease (like lupus or rheumatoid arthritis) that is the main problem.
- If you take hydroxychloroquine for Sjögren's, your dose must be 400 mg or less per day, and you must have been on the same dose for at least 4 weeks.
- You cannot have taken certain immune-suppressing drugs (like belimumab, abatacept, or cyclophosphamide) in the last 3 months, or certain cell-depleting therapies (like rituximab) in the last year.
- You must not have a current infection or a history of frequent serious infections.
- You must not have had cancer (except certain skin or cervical cancers) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This trial tests an experimental drug, IMVT-1402, in adults with primary Sjogren's disease who have moderate to severe symptoms. The goal is to see if it can reduce disease activity safely.
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
This trial tests an experimental drug called R-2487 for people with Sjogren's syndrome. It looks at safety and how well the drug works, and may offer a new treatment option.
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Hear when a new Sjögren's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.